135 related articles for article (PubMed ID: 37819139)
1. Benefits and harms of prostate specific antigen testing according to Australian guidelines.
Caruana M; Gulati R; Etzioni R; Barratt A; Armstrong BK; Chiam K; Nair-Shalliker V; Luo Q; Bang A; Grogan P; Smith DP; O'Connell DL; Canfell K
Int J Cancer; 2024 Feb; 154(4):648-658. PubMed ID: 37819139
[TBL] [Abstract][Full Text] [Related]
2. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
4. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
5. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
6. Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Cancer Epidemiol; 2023 Apr; 83():102338. PubMed ID: 36841020
[TBL] [Abstract][Full Text] [Related]
7. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
9. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
Li J; Zhao G; Hall IJ
Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
[TBL] [Abstract][Full Text] [Related]
10. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
11. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
[TBL] [Abstract][Full Text] [Related]
12. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
[TBL] [Abstract][Full Text] [Related]
13. A comparison of US and Australian men's values and preferences for PSA screening.
Howard K; Brenner AT; Lewis C; Sheridan S; Crutchfield T; Hawley S; Nielsen ME; Pignone MP
BMC Health Serv Res; 2013 Oct; 13():388. PubMed ID: 24093428
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
[TBL] [Abstract][Full Text] [Related]
15. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
16. The prostate-specific antigen test.
Roobol MJ
Expert Opin Med Diagn; 2013 Sep; 7(5):423-6. PubMed ID: 23875974
[TBL] [Abstract][Full Text] [Related]
17. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
18. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Wheeler DC; Szymanski KM; Black A; Nelson DE
BMC Cancer; 2011 Apr; 11():148. PubMed ID: 21510865
[TBL] [Abstract][Full Text] [Related]
19. PSA testing for men at average risk of prostate cancer.
Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
